Drug Discovery & Pharmaceuticals

RSS

Ingenza appoints new Strategic Business Advisor

Ingenza is excited to welcome Dr Mark Chadwick to the team as Strategic Business Advisor. Mark will bring extensive industry expertise to his new position at Ingenza, acquired over 30 years from a variety of roles within small growth companies, covering the areas of biotechnology, drug discovery and drug development.

23 Feb 2023

New prototype treatment proves effective against the venom of African and Asian elapid snakes

Prototype treatment for snake bite envenoming proves effective against the venom of African and Asian elapid snakes, such as some cobra, mamba, and krait species, new research shows.

23 Feb 2023

Novel fatty liver organoid models could aid in drug discovery and testing

Researchers from the Organoid group (former Clevers group, Hubrecht Institute) together with researchers from the Princess Máxima Center for pediatric oncology established novel human organoid models of fatty liver disease.

23 Feb 2023

Scientific advice on the terminal sterilization of oligonucleotide drug products

A new report, coauthored by several major pharmaceutical companies, reviews the current state of sterile oligonucleotide drug product processing.

22 Feb 2023

Brexanolone inhibits key systemic inflammatory pathways associated with post-partum depression

Post-partum depression (PPD) develops after childbirth and affects both the mother's and the infant's health by preventing healthy bonding.

20 Feb 2023

Activating or deactivating drugs with the help of light

Scientists at the Paul Scherrer Institute PSI have used the Swiss X-ray free-electron laser SwissFEL and the Swiss Light Source SLS to make a film that could give a decisive boost to developing a new type of drug.

20 Feb 2023

LLNL licensee and collaborators develop novel medicines to combat autoimmune diseases

People afflicted with autoimmune diseases may someday receive help through treatments now under development by a Lawrence Livermore National Laboratory licensee and its' collaborations with two major pharmaceutical companies.

17 Feb 2023

Small molecule inhibitor reverses malignant hyper-editing by an inflammation-induced protein isoform

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

16 Feb 2023

Repurposing or improving drugs for spinocerebellar ataxia type 5

A team of researchers has developed a new method to screen FDA-approved drugs to determine if they could be repurposed or improved to help patients with a rare, debilitating disease of the nervous system.

16 Feb 2023

Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

Inventia Life Science, a world leader in advanced cell models for biomedical research and drug discovery, today announced a collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) using Inventia’s RASTRUM™ 3D cell culture platform.

From Inventia Life Science 16 Feb 2023

Study could lead to a safe, on-demand and reversible oral contraceptive for men

In a mouse study, researchers funded by the National Institutes of Health have identified a potential non-hormonal contraceptive that men could take shortly before sexual activity and have fertility restored the next day.

14 Feb 2023

New analytical platform quantifies the structure of mRNA-based medicines

Researchers from Tokyo Metropolitan University and RIKEN CSRS have developed a new analytical platform based on liquid chromatography, mass spectrometry and software analysis that quantifies the structure of messenger RNA (mRNA) based medicines.

13 Feb 2023

Active compound from edible mushrooms boosts nerve growth and enhances memory

Researchers from The University of Queensland have discovered the active compound from an edible mushroom that boosts nerve growth and enhances memory.

10 Feb 2023

Researchers propose a pre-assembly strategy for efficient degradation of antibiotics

Recently, a research team led by Prof. KONG Lingtao from Institute of Solid State Research, Hefei Institutes of Physical Science of Chinese Academy of Sciences proposed a pre-assembly strategy to anchor single atoms on carbon nitride nanosheets.

9 Feb 2023

Researchers discover small molecules that can lock SARS-CoV-2 spike proteins

The infamous spike proteins on the surface of SARS-CoV-2 help it bind to and enter human cells. Because of their important role in spreading infection, these spike proteins are one of the main targets for COVID-19 vaccines and treatments.

9 Feb 2023

Researchers develop a new method to design peptide antibiotics

Hokkaido University researchers have developed a novel method to design and develop peptide antibiotics in large numbers, which will prove critical to controlling antibiotic resistance.

7 Feb 2023

Mucoactive drugs block SARS-CoV-2 infection

Researchers evaluate the effects of mucociliary active molecules on SARS-CoV-2 infection in vitro.

7 Feb 2023

AAHI awarded a $9.9 million project to develop prototype intranasal bivalent influenza RNA vaccine candidate

The Access to Advanced Health Institute announced today that it has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium Other Transaction Authority to develop a prototype intranasal bivalent influenza RNA vaccine candidate based on AAHI's self-amplifying RNA (saRNA) platform that targets both pandemic A(H5N1) and A(H7N9) influenza virus pathogens.

6 Feb 2023

New method can control the growth of a substance known to cause kidney stones in dolphins

In the body, crystals – made of things such as calcium or a collection of urine – form masses that can cause pain and serious health conditions.

5 Feb 2023

Oncodesign Services looks to the future

As Oncodesign evolves into Oncodesign Services and begins its journey as an independent business, CEO Fabrice Viviani explains his hopes and plans for the company’s future.

From Oncodesign Services 3 Feb 2023

Drug Discovery & Pharmaceuticals

Ingenza appoints new Strategic Business Advisor

New prototype treatment proves effective against the venom of African and Asian elapid snakes

Novel fatty liver organoid models could aid in drug discovery and testing

Scientific advice on the terminal sterilization of oligonucleotide drug products

Brexanolone inhibits key systemic inflammatory pathways associated with post-partum depression

Activating or deactivating drugs with the help of light

LLNL licensee and collaborators develop novel medicines to combat autoimmune diseases

Small molecule inhibitor reverses malignant hyper-editing by an inflammation-induced protein isoform

Repurposing or improving drugs for spinocerebellar ataxia type 5

Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

Study could lead to a safe, on-demand and reversible oral contraceptive for men

New analytical platform quantifies the structure of mRNA-based medicines

Active compound from edible mushrooms boosts nerve growth and enhances memory

Researchers propose a pre-assembly strategy for efficient degradation of antibiotics

Researchers discover small molecules that can lock SARS-CoV-2 spike proteins

Researchers develop a new method to design peptide antibiotics

Mucoactive drugs block SARS-CoV-2 infection

AAHI awarded a $9.9 million project to develop prototype intranasal bivalent influenza RNA vaccine candidate

New method can control the growth of a substance known to cause kidney stones in dolphins

Oncodesign Services looks to the future

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News